首页> 美国卫生研究院文献>Wiley-Blackwell Online Open >From On-Target to Off-Target Activity: Identification and Optimisation of Trypanosoma brucei GSK3 Inhibitors and Their Characterisation as Anti-Trypanosoma brucei Drug Discovery Lead Molecules
【2h】

From On-Target to Off-Target Activity: Identification and Optimisation of Trypanosoma brucei GSK3 Inhibitors and Their Characterisation as Anti-Trypanosoma brucei Drug Discovery Lead Molecules

机译:从目标上到目标外的活动:布鲁氏锥虫GSK3抑制剂的鉴定和优化及其表征为抗布鲁氏锥虫药物发现的先导分子

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Human African trypanosomiasis (HAT) is a life-threatening disease with approximately 30 000–40 000 new cases each year. Trypanosoma brucei protein kinase GSK3 short (TbGSK3) is required for parasite growth and survival. Herein we report a screen of a focused kinase library against T. brucei GSK3. From this we identified a series of several highly ligand-efficient TbGSK3 inhibitors. Following the hit validation process, we optimised a series of diaminothiazoles, identifying low-nanomolar inhibitors of TbGSK3 that are potent in vitro inhibitors of T. brucei proliferation. We show that the TbGSK3 pharmacophore overlaps with that of one or more additional molecular targets.
机译:非洲人锥虫病(HAT)是一种威胁生命的疾病,每年约有3万至4万例新病例。布鲁氏锥虫蛋白激酶GSK3(TbGSK3)短是寄生虫生长和生存所必需的。在此,我们报告了针对布鲁氏菌GSK3的聚焦激酶文库的筛选。由此我们确定了一系列几种高度配体有效的TbGSK3抑制剂。按照命中验证过程,我们优化了一系列二氨基噻唑,确定了TbGSK3的低纳摩尔抑制剂,它们是布鲁氏杆菌增殖的有效体外抑制剂。我们表明,TbGSK3药效团与一种或多种其他分子靶标重叠。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号